반응식
[Cl:1][C:2]1[CH:32]=[CH:31][CH:30]=[C:29]([Cl:33])[C:3]=1[CH2:4][C:5]1[S:6][C:7]2[N:8]=[C:9](S(C)(=O)=O)[N:10]=[C:11]([NH:14][C:15]3[CH:20]=[CH:19][C:18]([C:21]([F:24])([F:23])[F:22])=[CH:17][CH:16]=3)[C:12]=2[N:13]=1.[NH:34]1[CH2:39][CH2:38][O:37][CH2:36][CH2:35]1>C(O)(CC)(C)C>[Cl:33][C:29]1[CH:30]=[CH:31][CH:32]=[C:2]([Cl:1])[C:3]=1[CH2:4][C:5]1[S:6][C:7]2[N:8]=[C:9]([N:34]3[CH2:39][CH2:38][O:37][CH2:36][CH2:35]3)[N:10]=[C:11]([NH:14][C:15]3[CH:20]=[CH:19][C:18]([C:21]([F:23])([F:24])[F:22])=[CH:17][CH:16]=3)[C:12]=2[N:13]=1참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
반응 조건
- 온도
- 130 °C
실험 절차
To a mixture of [2-(2,6-dichloro-benzyl)-5-methanesulfonyl-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (49 mg, 0.1 mmol) in tert-amyl alcohol (2 mL) was added morpholine (24 mg, 0.3 mmol). The resulting mixture was heated to 130° C. in a sealed tube. After 12 h, the solution was cooled and purified by preparative reverse-phase HPLC to afford the title compound as a colorless solid (37 mg, 77%). MS (ESI): mass calcd. for C23H18Cl2F3N5OS, 539.0; m/z found, 540.0 [M+H]+. 1H NMR ((CD3)2SO): 10.14 (s, 1H), 8.10 (d, J=8.5 Hz, 2H), 7.70 (d, J=8.6 Hz, 2H), 7.61 (d, J=8.1 Hz, 2H), 7.49-7.42 (m, 1H), 4.69 (s, 2H), 3.66 (s, 8H).
후처리
- temperaturethe solution was cooled
- custompurified by preparative reverse-phase HPLC
출처 및 근거
- ORD 기록
- ord-ef391451dd594d7f91ea1601bec05317
- 출처 데이터셋
- uspto-grants-2014_01
- 특허 번호
- US08637527B2
연결된 노트
불러오는 중…